Vaso Corporation (VASO)

[thesmalls]

even without EECP - they should have a profitable year. GEHC commissions are backloaded and their 4Q13 should resemble 4Q11 for revenues and earnings. further, per the CC, they are expecting to ramp up with the new headcount brought on for GEHC so that should not only improve revenues QoQ, it should kick in the higher commission structure for 4Q13.

if i understood Ma correctly - BIOX had a $312K increase QoQ from last year and that is finally starting to reach critical mass. if they continue to accelerate growth in that area - that should provide an additional $1.5MM+ of revenues that was not present in 2012. the original acquisition was supposed to be accretive so there should be positive net income coming from those additional revenues on top of the GEHC.

Ma said in 1Q13 CC that they expected EECP sales to grow throughout the year. they were flat in 2Q13 and he did not reiterate his comments in the CC but he was also not asked about it.

any positive news concerning CMS reimbursement, new trial data with positive results in new indications (diabetes, Alzheimer's, ED, Parkinson's, ED, etc) and we will see that gap closed rather quickly ahead of positive year end.